Lanzhou Institute of Biological Products Co., Ltd clinical trials
Acquired by Sinopharm, Nov 2010 · source ↗
The registry lists 7 studies whose lead sponsor is Lanzhou Institute of Biological Products Co., Ltd. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 3, 2026.
Before and after it joined Sinopharm
- First submitted before Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm
- 0
- First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm
- 7
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Where
- China
- 4
Registry sponsor names on this page
- Lanzhou Institute of Biological Products Co., Ltd7 studies
Something wrong with this grouping? Tell us on the Sinopharm page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Sinopharm studies →
- A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal AntibodyNot yet recruitingNCT07445815Phase 2
Sponsor listed in the registry: Lanzhou Institute of Biological Products Co., Ltd · First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm
- Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody InjectionEnrolling by invitationNCT07149454Phase 1
Sponsor listed in the registry: Lanzhou Institute of Biological Products Co., Ltd · First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm
- Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLLStatus unknownNCT05557903Phase 1
Sponsor listed in the registry: Lanzhou Institute of Biological Products Co., Ltd · First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm
- A Study to Evaluate Botulinum Toxin Type A for Injection(HengLi®)for Prophylactic Treatment of Chronic MigraineStatus unknownNCT02291380Phase 3
Sponsor listed in the registry: Lanzhou Institute of Biological Products Co., Ltd · First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm
- A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)Status unknownNCT02786407Phase 3
Sponsor listed in the registry: Lanzhou Institute of Biological Products Co., Ltd · First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm
- A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb SpasticityCompletedNCT02280083Phase 3
Sponsor listed in the registry: Lanzhou Institute of Biological Products Co., Ltd · First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm
- A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate VaccineStatus unknownNCT02481232Phase 1
Sponsor listed in the registry: Lanzhou Institute of Biological Products Co., Ltd · First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm